What the ten-year data actually shows

For an athlete weighing up cartilage surgery, the ten-year data gives a clearer answer than most people expect.

The sharpest evidence comes from Gudas et al., published in the American Journal of Sports Medicine in 2012 — the only prospective randomised controlled trial conducted exclusively in young athletes that followed participants for a full decade. At the ten-year mark, the failure rate with OATS (mosaicplasty) stood at 14%, compared with 38% for microfracture — a 24-percentage-point gap that is both statistically significant (P<0.05) and clinically consequential.

That finding does not rest on one trial alone. Muthu et al.'s 2024 network meta-analysis, drawing on a broader pool of studies, independently reached the same directional conclusion: mosaicplasty produces significantly better functional outcomes at ten years than microfracture. Consistency across methodologically distinct sources — one athlete-specific RCT, one network meta-analysis — argues against a one-trial artefact and reinforces confidence in the direction of the evidence, even while acknowledging that this is not yet a body of dozens of randomised trials.

Why the gap only appears after five years

Surgeons who see this pattern regularly tend to find it predictable once the biology is understood.

In the Gudas RCT, both procedures produced broadly similar results in the early years — an observation that explains why studies with five-year or shorter follow-up have sometimes reported the two techniques as roughly equivalent. That comparison is accurate at the time-point measured; what it cannot capture is what happens next.

The divergence comes down to what each procedure actually deposits in the joint. Microfracture works by puncturing the subchondral bone to release marrow cells, which then form a repair tissue. That tissue is fibrocartilage — a structurally distinct material from the native hyaline cartilage it is meant to replace. Think of it as scar tissue in cartilage's clothing: it fills the defect and functions reasonably in the short term, but lacks the ordered collagen architecture that native cartilage uses to distribute load across the joint surface. Under years of athletic loading, that structural limitation compounds. By years five to ten in the Gudas series, microfracture outcomes were declining progressively whilst mosaicplasty results held stable — a trajectory that follows logically from the tissue biology rather than arriving as a surprise.

OATS takes a different approach. Intact osteochondral plugs — bone and hyaline cartilage together — are transferred from a lower-load region of the same joint. The transplanted tissue is structurally appropriate from the outset, which is reflected in the survival data over the decade.

Survival curves and when failures happen

Separate survival data gives those percentages a timeline — and the timing is where the clinical picture becomes most actionable for athletes.

Solheim et al. (2018), a Level III cohort study of 203 patients, reported overall long-term failure rates of 66% for microfracture versus 51% for OAT (P=0.01). The more telling finding is how those failures were distributed across time. Mean time to failure was 4.0 years with microfracture and 8.4 years with OAT — meaning the average OAT recipient maintained a functioning repair for more than twice as long before the procedure was considered to have failed.

The Kaplan-Meier survival curves make this concrete. OAT maintained greater than 80% survival for the first seven years and remained above 60% at fifteen years. Microfracture fell below 80% within twelve months and dropped below 60% within three years. In practical terms, within a year of microfracture, a meaningful proportion of patients were already on a declining trajectory — well before most athletes would regard their surgical recovery as complete.

The pattern held in a subgroup matched for age (under 51 years) and lesion size (under 500 mm²), with log-rank P=0.001, ruling out demographic imbalance as an explanation.

Solheim is a cohort study, not a randomised controlled trial, and that distinction matters. Its value is the survival-curve resolution it adds to the directional finding already established — confirming not just that more microfracture procedures ultimately fail, but showing precisely when that divergence accelerates.

Return to sport after each procedure

Getting back to sport at the same competitive level is typically the outcome athletes care most about — and the most recent pooled evidence gives a clear hierarchy.

Kunze et al. (2025), a systematic review reporting an overall pooled return-to-sport rate of 80.3% across cartilage restoration procedures, found OATS to have the highest likelihood of returning athletes to their sport at the same or greater level. Microfracture was the only procedure in the review associated with a lower likelihood of return to sport — a finding that sets it apart from every other technique included.

Lesion size sharpens this further. Pareek et al. (2016), a meta-analysis of prospective comparative studies with at least two years' follow-up, found OAT achieves higher activity levels and lower failure risk than microfracture specifically for cartilage defects greater than 3 cm² — a threshold that athletic injuries frequently exceed.

One factor athletes often raise is recovery timeline. OATS typically requires approximately six weeks of non-weight-bearing; microfracture involves a longer period — commonly four to seven months — before return to impact activities. Those are not equivalent measures, and published data do not support a clean like-for-like comparison of time to competitive sport between the two procedures. What the evidence does support is a clear verdict on long-term outcome: the difference in post-operative logistics is not a sound basis for choosing microfracture when the ten-year failure gap is as wide as the data show.

What OATS involves and its honest trade-offs

OATS is a single-stage procedure that uses the patient's own tissue. A cylindrical plug of bone and cartilage — carrying an intact surface layer of hyaline cartilage — is harvested from a relatively low-load area at the periphery of the femoral condyle and pressed into the prepared defect. The repair is therefore structural from the outset, using native cartilage architecture rather than the fibrocartilage fill that microfracture produces.

A single plug is suited to defects in the 1–2 cm² range. Where the lesion is larger, a mosaicplasty configuration — multiple smaller plugs arranged to tile the defect — can extend coverage to approximately 4 cm². Beyond that threshold, OATS does not provide adequate surface area; MACI, ACI, or fresh osteochondral allograft (OCA) become the more appropriate options. OATS is also not designed for diffuse or degenerative osteoarthritis — it is a focal-defect procedure, appropriate only where the surrounding joint cartilage is structurally sound.

The technique carries one limitation that is frequently underrepresented in outcome studies: donor-site morbidity. The harvest site can cause persistent aching, catching, or localised discomfort, and long-term data on its frequency and severity remain limited. This is not a reason to dismiss OATS, but it is a consideration that warrants explicit individual discussion before any decision is made — particularly for athletes whose entire lower limb is under sustained load.

Deciding which procedure is right for you

Several converging factors shape the choice of cartilage procedure — lesion size being the first.

Historically, microfracture was the default for defects below 2 cm²; OATS typically addresses the 1–2 cm² range, with a mosaicplasty configuration extending coverage to approximately 4 cm². For athletes with long-term sport goals, however, the ten-year outcome evidence makes microfracture difficult to justify even at the smaller end of that range — the failure-rate gap documented in the Gudas RCT and the Solheim survival analysis applies regardless of defect size.

Athlete age, activity demand, and prior treatment history all refine the decision further. Evidence suggests that a previous marrow-stimulation procedure raises failure rates in subsequent cell-based repair, so treatment sequencing matters — not just the current lesion in isolation. Lesion location also affects surgical access and plug geometry.

Determining OATS suitability requires MRI to map defect size, depth, grade, and subchondral bone integrity. Where those findings exceed OATS parameters, cell-based approaches such as MACI or ACI, or fresh osteochondral allograft, come into consideration instead.

A consultant-led assessment is the appropriate starting point. For patients in Lincolnshire, MSK Doctors' clinics in Sleaford (NG34) and Grantham (NG31) offer that assessment without the need for a GP referral; appointments can be arranged directly at mskdoctors.com.